AstraZeneca Says Phase 3 DeLLphi-305 Interim Analysis Showed IMFINZI Plus Amgen's Tarlatamab Met Primary Endpoint With Statistically Significant Overall Survival Improvement vs. IMFINZI Alone In Extensive-Stage Small Cell Lung Cancer

Benzinga Newsdesk www.benzinga.com Positive 95.5%

Neg 0% Neu 0% Pos 95.5%

Comments

No comments yet. Be the first!